Market Size and Growth
The Global Uveal Melanoma Treatment Market size reached US$ 1.54 billion in 2025 and is expected to reach US$ 2.7 billion by 2033, growing at a CAGR of 7.5% during the forecast period 2026-2033.
Uveal melanoma is a rare type of cancer that occurs in the tissues of the eye. Also called intraocular or ocular melanoma, this type of cancer occurs in only 5 people per million. However, it can resist treatment and spread quickly through the body. This malignant neoplasia is composed of atypical melanocytes. Melanocytes are cells that are normally found in the iris, ciliary body and choroid. A proliferation of atypical melanocytes that appear in any of these three structures forms an uveal melanoma. However, depending on its location and structure, each tumor has some particularities.
Choroidal melanoma is the most common subtype of uveal melanoma. Melanoma of the ciliary body is rarely seen. The anatomical location seems to be the key outcome. Surgical excision of the tumor, also known as iridectomy or iridocyclectomy, can be used for small, circumscribed iris and ciliary body melanomas with the removal of part of the iris as well as the adjacent ciliary body. The main treatment options for iris, ciliary body and choroid melanoma include radioactive plaque therapy and enucleation. A new type of Immunotherapy called, Tebentafusp (Kimmtrak) and HEPZATO KIT (Chemotherapy (melphalan hydrochloride) for injection/hepatic delivery system) was approved by the FDA to treat uveal melanoma.
Market Scope
| Metrics | Details |
| CAGR | 7.5% |
| Market Size | 2025-2033 |
| Market Estimation Forecast Period | 2026-2033 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Disease Type, Treatment and End-User |
| Regions Covered | North America, Europe, Asia-Pacific, South America and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report - Request for Sample
Market Dynamics
A surge in adoption of advanced cancer drug therapies
The surge in adoption of advanced cancer drug therapies is expected to drive the market over the forecast period. Advanced cancer drug therapies aim to address the unmet needs associated with uveal melanoma by providing better treatment. Some advanced cancer drug therapies have demonstrated improved efficacy and survival benefits. Immunotherapies, in particular, can harness the body's immune system to target and destroy cancer cells, leading to durable responses in some patients.
Advances in genomics and molecular biology have allowed for a better understanding of the genetic and molecular characteristics of individual tumors. This has paved the way for personalized medicine, where treatments are tailored to the specific genetic makeup of a patient's cancer. Targeted therapies are designed to interfere with specific molecules involved in cancer growth and progression. The chemotherapy (melphalan hydrochloride) for injection/hepatic delivery system (HEPZATO KIT) is an advanced therapy which was approved by the FDA.
For instance, on August 14, 2023, Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, cleared that the US Food and Drug Administration (FDA) approved HEPZATO KIT (melphalan/Hepatic Delivery System) as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues or lung that is amenable to resection or radiation.
Pharmaceutical companies and research institutions continue to invest heavily in the development of novel cancer therapies. This commitment to research and development has led to the discovery of new treatment modalities and innovative approaches. These increasing investments helps to increase the clinical trials to develop advanced cancer therapies to treat uveal melanoma.
For instance, in October 2023, iOnctura was granted an investigational new drug application for roginolisib by the FDA, with plans to launch a new Phase I trial. The FDA has granted its approval for the Swiss company to carry out clinical investigations into Roginolisib (IOA-244) as part of its investigational new drug (IND) application, which is aimed at treating conditions such as solid and haematologic malignancies, including uveal melanoma.
Further, the increasing prevalence of uveal melanoma, rising FDA approvals, increasing clinical trials and increasing awareness about uveal melanoma and their treatment options are the factors expected to drive the market over the forecast period.
Restraints
Factors such as complications associated with the various treatment therapies and surgery, the high cost of the uveal melanoma surgery and side effects associated with various therapeutics are the factors expected to hamper the market.
Market Segmentation Analysis
The global uveal melanoma treatment market is segmented based on disease type, treatment, end-user and region.
The immunotherapy segment accounted for approximately 59.6% of the uveal melanoma treatment market share
The immunotherapy segment is expected to hold the largest market share over the forecast period. Immunotherapy is a treatment that works by encouraging the immune system to attack cancer cells. The immunotherapy drug, tebentafusp is a type of treatment called a bispecific fusion protein. It works by helping immune cells get close enough to cancer cells to attack them. The clinical trial evaluated the drug as an initial treatment for people with metastatic uveal melanoma. The tebentafusp was approved by the FDA for the treatment of uveal melanoma.
For instance, on January 26, 2022, Immunocore Holdings plc, a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases cleared the approval from the United States Food and Drug Administration (FDA) for KIMMTRAK (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Tebentafusp is engineered to target a protein called gp100, which is expressed on the surface of uveal melanoma cells. By binding to gp100, Tebentafusp activates T cells, directing them to attack and kill the cancer cells. The drug promotes the activation of T cells, a critical component of the immune system. Activated T cells play a key role in recognizing and destroying cancer cells. Clinical trials have demonstrated encouraging results for Tebentafusp in treating metastatic uveal melanoma. The drug has shown effectiveness in improving overall survival compared to other treatments.
Market Geographical Share
North America accounted for approximately 42.6% of the market share
North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing research activities. North America especially the United States is known for its strong presence of major players such as pharmaceutical and medical device companies, which actively focus on the development of more advanced therapies to treat uveal melanoma.
Furthermore, increasing research activities also helps to develop more advanced therapeutics for the better management of the symptoms in the early stages. As the research activities increase, the therapeutics are developed more precisely by reducing the adverse effects and complications associated with the therapeutics, which results in better patient outcomes. There is an increasing number of clinical trials to develop more advanced treatment options for patients.
For instance, on June 6, 2023, Linnaeus Therapeutics, Inc. released the presentation of clinical data from its phase 1 dose-expansion study of LNS8801 as a monotherapy and in combination with pembrolizumab in metastatic uveal melanoma. LNS8801 alone and in combination with pembrolizumab was tolerable without unanticipated toxicities. LNS8801 demonstrated encouraging anti-tumor activity in patients with metastatic uveal melanoma, overall 50% of patients had disease control. These data support further development of LNS8801 alone and in combination with pembrolizumab as a therapeutic approach to treat metastatic uveal melanoma patients.
Market Major Players
The major global players in the uveal melanoma treatment market include Delcath Systems, Inc., Immunocore, Ltd., Eli Lilly and Company, iOnctura SA, Linnaeus Therapeutics, Inc., AstraZeneca Plc., IDEAYA Biosciences, Inc., Verastem, Inc., Foghorn Therapeutics and InxMed among others.
Recent Developments
April 2026: Breakthrough Phase 2/3 Trial Success in First-Line Metastatic Uveal Melanoma
A major milestone was achieved when a combination therapy (darovasertib + crizotinib) demonstrated statistically significant improvement in progression-free survival (6.9 months vs 3.1 months) and strong tumor response rates in a registrational Phase 2/3 trial. This marks one of the most important late-stage clinical advancements for HLA-A*02:01-negative metastatic uveal melanoma, supporting upcoming regulatory submission for accelerated approval.
April 2026: Shift Toward Targeted MAPK/PKC Pathway Inhibitor Combinations
The treatment landscape is increasingly moving toward dual-targeted precision therapies, especially combinations involving PKC inhibition and MET/MEK pathway modulation. These regimens are showing superior outcomes compared to traditional off-label immunotherapies, signaling a structural shift in first-line metastatic uveal melanoma treatment strategy.
March 2026: Liver-Directed Regional Therapy Gains Formal Clinical Guideline Recognition
Percutaneous hepatic perfusion (melphalan-based liver-directed therapy) was formally included in updated European clinical practice guidelines for metastatic uveal melanoma, reinforcing its role as a key intervention for liver-dominant disease. This reflects growing acceptance of locoregional treatments alongside systemic therapies.
March 2026: Expanding Use of Combination Immunotherapy in Clinical Trials
Multiple Phase 2 studies reported ongoing evaluation of checkpoint inhibitor combinations (anti–CTLA-4 + anti–PD-1) with liver-directed therapies, aiming to overcome historically low response rates in uveal melanoma. Early findings suggest improved tumor immune activation, although survival data remain immature.
Why Purchase the Report?
- To visualize the global uveal melanoma treatment market segmentation based on disease type, treatment, end-user and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous data points of uveal melanoma treatment market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global uveal melanoma treatment market report would provide approximately 61 tables, 63 figures, and 187 Pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
